ImmunoGen Teams Up With Huadong Medicine to Develop Mirvetuximab in China

ImmunoGen Teams Up With Huadong Medicine to Develop Mirvetuximab in China
ImmunoGen has announced a collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co, a subsidiary of Huadong Medicine, to develop and commercialize the ovarian cancer treatment mirvetuximab soravtansine to patients in China, Hong Kong, Macau, and Taiwan. The partnership will combine ImmunoGen's expertise in cancer medication development with Huadong Medicine's familiarity with regulatory agencies and connections to healthcare organizations within the Asian countries. "With extensive regional experience, the right development and regulatory capabilities, and access to a deep local network of hospitals and clinics across Greater China, Huadong Medicine is an ideal partner for us,” Mark Enyedy, president and CEO of ImmunoGen, said in a press release. The subject of the companies' collaboration, mirvetuximab soravtansine, is an antibody-drug conjugate or ADC, a class of medications that combine monoclonal antibodies and anti-cancer agents. The antibodies are targeted against a certain cancer protein, which allows the toxic agent to be delivered specifically to cancer cells. In the instance of mirvetuximab soravtansine, known as mirvetuximab, the antibody targets the protein folate receptor alpha, which is overly produc
Subscribe or to access all post and page content.